<i>In Silico</i> Approaches for Investigating the Binding Propensity of Apigenin and Luteolin Against Class I HDAC Isoforms

Abstract

Apigenin and luteolin may serve as substitutes to synthetic inhibitors for effective HDAC based anticancer therapy.